Evicenter
MarkdownMedical informationP&T meetings
Rinzimetostat (ORIC-944)

Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide

Regulatory status
Not announced
Launch
Not announced
Last updated
165 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatment

Place in treatment, anticipated use, and care setting

10 evidence topics · 12 sources

Summary

Rinzimetostat is investigational; ORIC has not submitted for or obtained regulatory approval for any product candidate. Himalayas-1 (NCT07723248) is a global, randomized, open-label phase 3 trial of rinzimetostat plus darolutamide compared with a prespecified physician’s choice of an ARPI or docetaxel in approximately 600 participants with mCRPC previously treated with abiraterone. The trial requires disease progression on abiraterone in the metastatic castration-sensitive or first-line mCRPC setting, permits docetaxel for castration-sensitive disease, and excludes prior cytotoxic chemotherapy otherwise, radioligand therapy, and apalutamide, darolutamide, or enzalutamide; it was recruiting with an actual start of 2026-08-03 and an estimated primary completion of 2028-03. The proposed position is therefore after abiraterone and before chemotherapy, radioligand therapy, or a second ARPI for castration-resistant disease. A separate phase 3 trial evaluates another PRC2 inhibitor, mevrometostat, plus enzalutamide against physician’s choice of enzalutamide or docetaxel in mCRPC after at least 12 weeks of abiraterone.

Both components of the regimen are oral: participants are randomized 1:1 to rinzimetostat 400 mg once daily plus darolutamide 600 mg twice daily, while the docetaxel control is given at 75 mg/m2 intravenously every 21 days for up to 10 cycles. The darolutamide label lists non-metastatic castration-resistant and metastatic castration-sensitive prostate cancer (alone or with docetaxel), without mCRPC, and requires a concurrent gonadotropin-releasing hormone agonist or antagonist or prior bilateral orchiectomy.

ORIC estimated the U.S. population at approximately 17,000 men per year with mCRPC previously treated with abiraterone and an addressable market of more than $3.5 billion, reported that abiraterone, the leading ARPI, has maintained more than 50% market share of new prescriptions over the last five years, and stated that this market “lacks oral, well-tolerated therapies with meaningful efficacy”. ORIC is also exploring rinzimetostat in other populations, including post-AR inhibitor mCRPC, and lists a second phase 3 trial (Himalayas-2) with apalutamide. These are company statements that are not peer reviewed.

The regimen pairs rinzimetostat with a second ARPI in a setting where the EAU guideline advises avoiding sequencing of androgen receptor-targeted agents, recommends chemotherapy after an ARPI, and states that an ARPI-ARPI sequence “should never be the preferred option”. In U.S. practice, a second ARPI is nonetheless the most frequent choice: 459 of 804 ARPI-experienced patients with mCRPC (57.1%) received another ARPI and 192 (23.9%) chemotherapy; among 1,519 Medicare patients with prior novel hormonal therapy, 70% received novel hormonal therapy as first-line mCRPC treatment, 7% chemotherapy, and 13% no subsequent life-prolonging therapy. In another real-world cohort, 48.4% received a sequential ARPI and 35% docetaxel as index therapy, abiraterone followed by docetaxel (16.1%) and abiraterone followed by enzalutamide (10.9%) were the most common sequences, and taxane use was 42% to 46% with ECOG performance status 0 to 1 and 29% with ECOG 2 or higher. The initial ARPI is increasingly given before castration resistance: in pre-mCRPC settings in 82.6% of patients in that cohort, and as ARPI-only treatment before mCRPC diagnosis in 34.8% of a U.S. cohort in 2023, compared with 10.3% in 2018.

US real-world treatment after a prior androgen receptor pathway inhibitor